Targeted Delivery of Anti-Inflammatory Agents to Tumors

Author(s): Maria Coimbra, Sylvia A. Kuijpers, Sebastiaan P. van Seters, Gert Storm, Raymond M. Schiffelers

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 16 , 2009

Become EABM
Become Reviewer
Call for Editor


Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [1825 - 1843]
Pages: 19
DOI: 10.2174/138161209788453220
Price: $65

Article Metrics

PDF: 22